114.20
-2.58(-2.21%)
Currency In USD
| Previous Close | 116.78 |
| Open | 116.19 |
| Day High | 116.87 |
| Day Low | 112.79 |
| 52-Week High | 139.13 |
| 52-Week Low | 75.56 |
| Volume | 512,016 |
| Average Volume | 627,811 |
| Market Cap | 5.7B |
| PE | -22.89 |
| EPS | -4.99 |
| Moving Average 50 Days | 112.11 |
| Moving Average 200 Days | 108.31 |
| Change | -2.58 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $13,066.36 as of September 16, 2025 at a share price of $114.2. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,413.89 as of September 16, 2025 at a share price of $114.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast it
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chie
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
GlobeNewswire Inc.
Jul 09, 2025 11:00 AM GMT
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for